Evidence map›Paper›PMID 39654365›Full record

ReviewCNS neuroscience & therapeutics2024

The Compelling Role of Brain-Derived Neurotrophic Factor Signaling in Multiple Sclerosis: Role of BDNF Activators.

Hayder M Al-Kuraishy, Ghassan M Sulaiman, Hamdoon A Mohammed, Salim Albukhaty, Ali K Albuhadily, Ali I Al-Gareeb, Daniel J Klionsky, Mosleh M Abomughaid

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Curcumin-Piperine Self-Nanoemulsifying Delivery inPharmaceuticals (Basel, Switzerland) · 2025
    Article
  9. Antioxidants (Basel, Switzerland) · 2025
    Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hayder M Al-KuraishyDepartment of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Ghassan M SulaimanDivision of Biotechnology, Department of Applied Sciences, University of Technology, Baghdad, Iraq.ORCID 0000-0001-6388-3849
Hamdoon A MohammedDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim, Saudi Arabia.
Salim AlbukhatyAl-Manara College for Medical Sciences, Amarah, Maysan, Iraq.ORCID 0000-0001-7885-4215
Ali K AlbuhadilyDepartment of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Ali I Al-GareebJabir ibn Hayyan Medical University, Kufa, Najaf, Iraq.
Daniel J KlionskyLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA.
Mosleh M AbomughaidDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia.

Funding

ALTERNATIVE VACUOLAR TARGETING MECHANISMS IN YEASTR01GM053396 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 1995 to 2005
$2.7M
The mechanism and regulation of autophagyR35GM131919 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2025 to 2025
$774k
NIGMS NIH HHS R01 GM053396NIGMS NIH HHS R35 GM131919
6 · The paper itself

Abstract

Brain-derived neurotrophic factor (BDNF) is a neurotrophin, acting as a neurotrophic signal and neuromodulator in the central nervous system (CNS). BDNF is synthesized from its precursor proBDNF within the CNS and peripheral tissues. Through activation of NTRK2/TRKB (neurotrophic receptor tyrosine kinase 2), BDNF promotes neuronal survival, synaptic plasticity, and neuronal growth, whereas it inhibits microglial activation and the release of pro-inflammatory cytokines. BDNF is dysregulated in different neurodegenerative diseases and depressions. However, there is a major controversy concerning BDNF levels in the different stages of multiple sclerosis (MS). Therefore, this review discusses the potential role of BDNF signaling in stages of MS, and how BDNF modulators affect the pathogenesis and outcomes of this disease.

Indexed as

Brain-Derived Neurotrophic FactorMultiple SclerosisSignal TransductionAnimalsHumansReceptor, trkBBrain-Derived Neurotrophic FactorReceptor, trkBbrain‐derived neurotrophic factormultiple sclerosisneuromodulatorpathogenesistropomyosin receptor kinase B

Identifiers

PMID39654365
PMCPMC11628746

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.